Learning outcomes
By the end of this lesson you should be able to: distinguish grading from staging and state what each predicts; interpret a TNM classification and derive a stage group; describe the major biopsy and cytology techniques with the questions each answers; name the common tumour markers, the tumours they follow, and their limitations; and explain how immunohistochemistry confirms a diagnosis and selects a therapy.
Prerequisites
Lessons 10-12. Grading and staging describe how far a neoplasm's biology has gone, so the benign/malignant classification and the hallmarks of the previous lessons underpin it. Histological interpretation is applied lesson 1's cell-injury morphology.
The big idea
The two axes are independent and both matter. A well-differentiated follicular thyroid carcinoma is a low-grade cancer that nevertheless metastasises and is a stage IV disease at diagnosis; a poorly differentiated carcinoma may still be stage I if caught early. The stage, not the grade, decides how far surgery should reach; the grade, not the stage, predicts the aggressiveness that determines the strength of adjuvant treatment. Above all, a grade or stage is only meaningful attached to the tumour's site — a T2 bladder tumour and a T2 lung tumour are different worlds.
Grading
| Axis | What is used |
|---|---|
| Differentiation | How closely the tumour cells and architecture resemble the parent tissue — graded well (G1), moderate (G2), poor (G3) and undifferentiated (G4) |
| Mitotic rate | Counted mitoses per high-power field; a faster rate is worse |
| Nuclear pleomorphism | Variation in nuclear size, shape and chromatin |
| Organ-specific scores | Gleason grade (prostate architecture: patterns 1-5 summed to a score); Nottingham grade (tubule formation + nuclear pleomorphism + mitoses for breast); FIGO grading for some gynaecological tumours |
Three practical caveats belong here. Grade is sampled from a representative area, because a tumour is heterogeneous — its highest grade may lie in a region the needle missed, or in the deepest part of the mass, so a biopsy grade is often a floor and undergrades more often than it overgrades. Grade is a pathology report, not a blood test, and it is sometimes not assessable after preoperative treatment. And uniformity may be misleading: neuroendocrine tumours look uniform under the microscope but behave aggressively, so architecture is not the whole truth.
The TNM staging system
| Component | Classification | Meaning |
|---|---|---|
| T — the primary tumour | T0 to T4 (sometimes Tis for carcinoma in situ) | Size and/or depth of local invasion, defined per organ |
| N — the regional lymph nodes | N0 to N3 | Number and site of involved nodes (often the strongest single prognostic factor) |
| M — distant metastasis | M0 or M1 | Distant metastasis present or absent; M1 is almost always incurable |
The TNM letters are then combined into stage groups I to IV, which is the shorthand you will see in tumour registries and trials: roughly, stage I is a localised small tumour, stage II a larger local tumour without nodes, stage III node-positive disease, and stage IV metastatic disease. The system is maintained by the AJCC/UICC and updated by organ; the prefix c is added for clinical staging (before resection) and p for pathologists' staging after resection. Pathological stage is more accurate than clinical because it counts actual nodes and the true depth.
A colonoscopy shows a 3 cm tumour in the sigmoid colon. Histology and a CT show it invading the muscularis propria, two of twelve nodes are positive, and CT shows no liver metastases. The classification is T2 N1 M0 — a node-positive disease, stage III. It changes the plan from endoscopic follow-up alone to colectomy with node clearance and consideration of adjuvant chemotherapy; the presence of stage III disease is the reason adjuvant chemotherapy is even discussed.
| Stage group | TNM pattern | General meaning | Typical treatment implication |
|---|---|---|---|
| Stage I | T1-2 N0 M0, no high-risk features | Local tumour, no nodes | Local therapy (surgery alone) is often sufficient |
| Stage II | Larger local tumour, still N0 M0 | Local disease, higher recurrence risk | Local therapy plus consideration of adjuvant therapy for high-risk features |
| Stage III | Any T, N1-3 M0 | Node involvement | Combination of surgery with node clearance and adjuvant systemic therapy |
| Stage IV | Any T, any N, M1 | Metastatic disease | Systemic therapy; local treatment only for symptoms or for control |
Diagnosis: biopsy, cytology, molecular
| Method | What is taken | What it is used for |
|---|---|---|
| Fine-needle aspiration | Cells only, no tissue architecture | Rapid triage — distinguishing a cyst from a solid lesion; convenient for node, thyroid and breast |
| Core needle biopsy | A small cylinder preserving architecture | The technique of choice for breast and prostate diagnosis, and for grading |
| Incisional biopsy | A piece of a larger tumour | Diagnosis when the diagnosis requires architecture but complete excision would be disfiguring |
| Excisional biopsy | The whole lesion | Melanoma and most small lesions — both diagnosis and treatment |
| Frozen section | A frozen slice inside theatre | Decides during surgery whether a margin is clear or a sentinel node is positive |
| Cytology | Shed or scraped cells | Cervical screening (Pap smear), urine, effusions |
| Immunohistochemistry | Stains applied to the histology slide | Cell of origin, grade markers, and therapeutic targets — ER, PR and HER2 in breast carcinoma; CK and CD45; TTF-1 for lung |
| Molecular testing | DNA or RNA extracted from the tumour | Driver mutations that determine targeted therapy — EGFR and ALK in lung adenocarcinoma, BRAF in melanoma, KRAS in colorectal, HER2 in gastric |
Tumour markers
| Marker | Main association | Real clinical use |
|---|---|---|
| PSA (prostate-specific antigen) | Prostate epithelium | Early detection and follow-up at best; elevated in benign hyperplasia, prostatitis and after instrumentation, so a positive biopsy, not the level, makes the diagnosis |
| CA-125 | Ovarian carcinoma | Follow-up of a treated ovarian carcinoma; not adequate for population screening |
| Carcinoembryonic antigen (CEA) | Colorectal carcinoma (and smoking) | Follow-up after resection of colorectal carcinoma; not for diagnosis |
| Alpha-fetoprotein | Hepatocellular carcinoma, germ cell tumours | A level of 500 ng/ml or more with a liver nodule is near-diagnostic of HCC; also used for germ cell follow-up |
| Beta-hCG | Trophoblastic tumours, germ cell tumours | Diagnosis and follow-up of hydatidiform mole and choriocarcinoma; elevated AFP in germ cell tumours indicates yolk sac |
| CA 19-9 | Pancreatic adenocarcinoma | Follow-up; not specific enough for screening and not always elevated in advanced disease |
| Calcitonin | Medullary thyroid carcinoma | Baseline measurement and family screening in MEN2, where it is a true genetic screening test |
| HER2 | Breast carcinoma | Not a blood marker: detected on the tumour; it is essential for prescribing trastuzumab |
| Lactate dehydrogenase | Lymphoma, germ cell tumours | Bulk of disease and a prognostic variable in treatment protocols |
Watch outThe correct use of tumour markers is almost always monitoring a known tumour — after treatment and then for relapse — not detecting a cancer that has not been found. Using CA-125 or PSA to screen an asymptomatic population causes overdiagnosis, false positives and harm, which is why screening protocols use the marker in combination with imaging or not at all.
Common mistakes
Watch outSaying grade and stage mean the same thing. Grade = microscopic differentiation; stage = anatomic spread. A low-grade advanced tumour kills; a high-grade early tumour is cured.
Watch outTreating a raised CEA or CA-125 as proof of advanced cancer. Both rise in benign disease, both can be normal in cancer, and neither replaces a scan or a biopsy. The correct statement is that a rising marker after a completed treatment is more informative than a single elevated one.
Watch outSaying immunohistochemistry is a blood test. It is a stain applied to the tissue, and its real power is cell-of-origin classification and the detection of therapeutic targets — HER2, hormone receptors, mismatch repair status — not simply identifying the tumour's name.
Check your understanding
A 2 cm breast carcinoma is found in one of three axillary nodes; there are no liver metastases. What is the TNM, and why does it matter surgically?
Why does the biopsy see a more moderate grade of the tumour than the resection specimen in some patients?
Why is a rising AFP a much more useful test than a raised one?
Multiple choice
Which best describes the relationship between grading and staging?
A patient's colon cancer is 4 cm, invades the pericolic fat, has one node involved, and CT shows a single 1 cm liver metastasis. What is the stage?
Which technique would a surgeon most appropriately use to decide the width of breast excision in theatre?
Which tumour marker is best used as a true screening test, because of its mode of inheritance?
Which statement about the interpretation of a raised CA-125 is correct?
Summary and next
Grade and stage answer different questions: grade measures how closely the tumour resembles its tissue of origin, via differentiation, mitoses and organ-specific scores, and predicts behaviour; stage measures anatomical spread, via TNM and the stage groups, and decides the treatment. Biopsy and cytology give the tissue; immunohistochemistry and molecular testing give the cell of origin and the target; and tumour markers are most honest when they are used to monitor treatment and detect recurrence, not to diagnose cancer. A rising marker after therapy is a question asked of the tumour, not a verdict delivered by a number.
Next: the endocrine and haematological aspects are left to the systemic lessons; this module ends with the paraneoplastic syndromes and tumour immunology that connect the neoplasm to the rest of the body.